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ABSTRACT 
Context: Risk profiling of oncology patients based on their symptom experience assists 
clinicians to provide more personalized symptom management interventions. Recent findings 
suggest that oncology patients with distinct symptom profiles can be identified using a variety of 
analytic methods. 
Objectives: To evaluate the concordance between the number and types of subgroups of 
patients with distinct symptom profiles using latent class analysis (LCA) and K-modes analysis. 
Methods: Using data on the occurrence of 25 symptoms from the Memorial Symptom 
Assessment Scale (MSAS), that 1329 patients completed prior to their next dose of 
chemotherapy (CTX), Cohen’s kappa coefficient was used to evaluate for concordance between 
the two analytic methods. For both LCA and K-modes, differences among the subgroups in 
demographic, clinical, and symptom characteristics, as well as quality of life outcomes were 
determined using parametric and nonparametric statistics.  
Results: Using both analytic methods, four subgroups of patients with distinct symptom profiles 
were identified (i.e., All Low, Moderate Physical and Lower Psychological, Moderate Physical 
and Higher Psychological, All High). The percent agreement between the two methods was 
75.32% which suggests a moderate level of agreement. In both analyses, patients in the All 
High group were significantly younger and had a higher comorbidity profile, worse MSAS 
subscale scores, and poorer QOL outcomes. 
Conclusion: Both analytic methods can be used to identify subgroups of oncology patients with 
distinct symptom profiles. Additional research is needed to determine which analytic methods 
and which dimension of the symptom experience provides the most sensitive and specific risk 
profiles. 
 
Key words: symptom clusters; cancer; latent class analysis; machine learning; clustering; 
chemotherapy, k-modes analysis  
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INTRODUCTION 
 Both clinical experience and research findings suggest that oncology patients 
experience significant interindividual variability in their symptom experience.1,2 In the era of 
precision medicine,3 which focuses on the identification of patients who are at greater risk for 
chronic conditions like cancer, it is imperative that the optimal methods to risk profile patients 
based on their symptom burden is identified. In two reviews of the state of the science in 
symptom clusters research,4,5 it was noted that future studies need to focus on an evaluation of 
the concordance between the various analytic methods that can be used to identify patients who 
are at greatest risk for a higher symptom burden.  
Recent findings from our group6-14 and others15-18 have identified subgroups of patients 
with distinct symptom experiences using approaches like hierarchical cluster analysis and latent 
class analysis (LCA). In the earliest of these studies,6,7,15,16 different clustering methods were 
used to create the patient subgroups. In the later studies,9-14,18 LCA was the preferred analytic 
approach. While across these thirteen studies, the number of subgroups ranged from two to 
five, a common finding across all of these studies was the identification of a group of patients 
who reported low levels of symptoms and a group of patients who reported high levels of 
symptoms. However, none of these studies determined whether the use of two different analytic 
approaches produces congruent results (e.g., the percentages of patients in the “all high” 
groups are equal and are the same patients).  
As noted in a recent review,5 machine learning techniques may provide useful 
approaches to identify subgroups of patients with distinct symptom profiles. Some specific 
machine learning techniques that can be used for this purpose include: K-means,19 K-
modes,20,21 spectral clustering,22 birch,23 or agglomerative hierarchical clustering (AHC).24,25 For 
binary variables (e.g., symptom occurrence), K-means and K-modes are two centroid based 
algorithms that calculate the distance between each pair of data points using Euclidean distance 
or a simple dissimilarity measure (e.g., Hamming distance), respectively. The clusters derived 
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from K-means and K-modes analyses are described by the “centroid”, which is the 
multidimensional mean and mode, respectively, of the samples inside them.19,21 Spectral 
clustering is a graph distance based algorithm that performs a dimensionality reduction before 
clustering the lower-dimension dataset in a similar fashion to K-means. It is used when the 
clusters are not linearly separated in the original space, providing better results than algorithms 
such as K-means (which tends to find spherical clusters).26 Birch is a hierarchical clustering 
algorithm that can provide an advantage in datasets that are non-uniformly distributed and every 
data point is not equally important. It concentrates on densely occupied partitions and follows a 
hierarchical order of analysis that focuses on calculating and updating measurements that 
capture the natural closeness of data. Therefore, it is more robust to “noise” (i.e., data points 
that are not part of the underlying pattern).23 Finally, AHC is a decision tree, bottom-up 
clustering method that starts with every single data point in a single cluster. In each successive 
iteration, it agglomerates (merges) the closest pair of clusters by satisfying a similarity criterion, 
until all of the data are in one cluster. A matrix tree plot visually demonstrates the hierarchy 
within the final cluster, where each merger is represented by a binary tree. AHC can be both 
informative for data display and helpful for the discovery of smaller clusters.24 
No studies were identified that evaluated for congruence between two methods of 
classifying oncology patients based on their distinct experiences with common symptoms 
associated with cancer treatment. Based on how well the machine learning methods described 
above performed during our initial analyses,27 for this paper, K-modes was selected as the 
method to compare with LCA. The purpose of this study, in a sample of patients (n=1329) who 
were undergoing chemotherapy (CTX) for breast, lung, gastrointestinal (GI), or gynecological 
(GYN) cancers was to evaluate the concordance between the number and types of subgroups 
of patients with distinct symptom experiences that were identified using LCA and K-modes 
analyses. We hypothesized that the number and types of subgroups would be similar using 
these two analytic methods. 
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METHODS 
Patients and Settings 
 This study is part of a longitudinal study of the symptom experience of oncology 
outpatients receiving CTX. The methods for this study are described in detail elsewhere.13,28,29 
According to the study’s eligibility criteria: patients were ≥18 years of age; had a diagnosis of 
breast, GI, GYN, or lung cancer; had received CTX within the preceding four weeks; were 
scheduled to receive at least two additional cycles of CTX; were able to read, write, and 
understand English; and gave written informed consent. Patients were recruited from two 
Comprehensive Cancer Centers, one Veteran’s Affairs hospital, and four community-based 
oncology programs.  
Instruments 
 A demographic questionnaire obtained information on age, gender, ethnicity, marital 
status, living arrangements, education, employment status, and income. The Karnofsky 
Performance Status (KPS) scale30 was used to evaluate patients’ functional status. The Self-
administered Comorbidity Questionnaire (SCQ)31 evaluated the occurrence, treatment, and 
functional impact of thirteen common comorbid conditions (e.g., diabetes, arthritis). 
 A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to 
evaluate the occurrence, severity, frequency, and distress of 38 symptoms commonly 
associated with cancer and its treatment. In this study, six symptoms were added to the original 
list of 32 MSAS symptoms (i.e., hot flashes, chest tightness, difficulty breathing, abdominal 
cramps, increased appetite, weight gain). The MSAS is a self-report questionnaire designed to 
measure the multidimensional experience of symptoms. Patients were asked to indicate 
whether or not they had experienced each symptom in the past week (i.e., symptom 
occurrence). If they had experienced the symptom, they were asked to rate its frequency of 
occurrence, severity, and distress. The reliability and validity of the MSAS is well established in 
oncology patients.32,33 
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 Three subscale scores (i.e., physical [MSAS-PHYS], psychological [MSAS-PSYCH], 
global distress index [MSAS-GDI]) were calculated. The MSAS-PHYS is the average of the 
frequency, severity, and distress ratings for twelve physical symptoms (i.e., lack of energy, 
feeling drowsy, pain, nausea, vomiting, change in the way food tastes, lack of appetite, dry 
mouth, constipation, feeling bloated, dizziness, and weight loss). The MSAS-PSYCH is the 
average of the frequency, severity, and distress ratings for six psychological symptoms (i.e., 
worrying, feeling sad, feeling nervous, feeling irritable, difficulty in sleeping, difficulty 
concentrating). The MSAS-GDI is the average of the distress ratings for six physical symptoms 
(i.e., lack of energy, feeling drowsy, pain, lack of appetite, dry mouth, constipation) and the 
frequency ratings for four psychological symptoms (i.e., worrying, feeling sad, feeling nervous, 
feeling irritable).  
Quality of life (QOL) was evaluated using disease-specific (i.e., Quality of Life Scale-
Patient Version (QOL-PV))34-36 and generic (i.e., Medical Outcomes Study-Short Form-12 (SF-
12))37 measures. The QOL-PV is a 41-item instrument that measures four dimensions of QOL 
(i.e., physical, psychological, social, and spiritual well-being) in oncology patients, as well as a 
total QOL score. Each item is rated on a 0 to 10 numeric rating scale (NRS) with higher scores 
indicating a better QOL. The QOL-PV has established validity and reliability.36,38-40 
The SF-12 consists of 12 questions that evaluate physical, mental, and overall health 
status. Individual items on the SF-12 are evaluated. In addition, the instrument is scored into 
physical component summary (PCS) and mental component summary (MCS) scores. These 
scores can range from 0 to 100. Higher PCS and MCS scores indicate a better QOL. The SF-12 
has well established validity and reliability.37 
Study Procedures 
 The study was approved by the Committee on Human Research at the University of 
California, San Francisco and by the Institutional Review Board at each of the study sites. 
Written informed consent was obtained from all patients. For this analysis, symptom occurrence 
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data from the enrollment assessment, that asked patients to report on their symptom experience 
for the week prior to the administration of the next cycle of CTX, were analysed (i.e., recovery 
from previous CTX cycle).  
Data Analyses 
Symptom Occurrence Data 
In order to have a sufficient number of patients who endorsed each symptom, the LCA 
and K-modes analyses were done with the 25 symptoms that occurred in ≥30% of the patients 
(i.e. difficulty concentrating, pain, lack of energy, cough, feeling nervous, hot flashes, dry mouth, 
nausea, numbness or tingling in hands or feet, feeling drowsy, difficulty sleeping, feeling 
bloated, diarrhea, feeling sad, sweats, problems with sexual interest or activity, worrying, lack of 
appetite, dizziness, feeling irritable, hair loss, constipation, change in the way food tastes, I do 
not look like myself, changes in skin). 
Latent Class Analysis  
 LCA identifies latent classes based on an observed response pattern.41,42 It is a 
statistical method for finding subtypes of related cases (i.e., latent classes) from multivariate 
categorical data. The LCA was performed using MplusTM Version 7.43 Estimation was carried out 
with robust Maximum-Likelihood (MLR) and the Expectation-Maximization (EM) algorithm.44 The 
optimal number of latent classes for this LCA was selected based on the Bayesian Information 
Criterion (BIC), the Vuong, Lo, Mendel, and Rubin (VLMR) likelihood ratio test, and entropy. 
Theoretically, the best fitting LCA model has the lowest BIC. Nevertheless, the BIC can be 
supplemented by an evaluation of the VLMR45 which tests whether a model with K classes fits 
the data better than a model with one fewer class (the K-1 class model). When this VLMR is 
significant, the K-class model is considered to be a better fit for the data. When models are 
evaluated sequentially, with each new model having one more class than the previous model, if 
a model is identified for which the VLMR is not significant, then too many classes were 
extracted and the K-1 class model is considered to fit the data better than the current K-class 
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model. Furthermore, well-fitting models produce entropy values of ≥0.80.46 In addition, the 
optimal fitting model should “make sense” conceptually and its classes should differ as might be 
expected on variables not used in the generation of the model. 
K-modes analysis 
K-modes is a centroid method that is optimized for use with categorical variables.21 It 
defines clusters based on the number of matching categories between data points and not on 
their Euclidean distance (a common similarity index in agglomerative clustering methods). 
Although its performance is comparable to K-means,27 the K-modes distance measurement 
approach is theoretically a more appropriate approach to use to cluster the categorical variable 
of symptom occurrence.21,47 The K-modes analysis was implemented with PyCharm 
Professional Edition 4.5 and the Scikit-Learn library.48 
The optimal number of clusters for the K-modes analysis was assessed using the 
Silhouette Coefficient (SC).49 The SC represents how well each case (i.e., patient) lies within its 
cluster and how appropriate each case’s assignment is inside a specific cluster. The average 
SC, called the Silhouette Index (SI), allows one to evaluate the overall quality of the separation 
between the clusters. The SC is calculated using its intra-cluster distance and its nearest-cluster 
distance.27 The SC is bounded between -1 for inappropriate clustering and +1 for highly 
compact clustering. A SC around zero indicates that a case is assigned inside overlapping 
clusters. In general, the average SI is high when clusters are dense and well separated. 
Evaluation of Congruence 
In order to evaluate the congruence between the LCA and K-modes solutions (i.e., 
number of subgroups identified), we compared the solutions using SCI diagrams (see Figures 
1A and 1B, respectively).49 When the SC for a case is >0, its assignment to this cluster is 
considered appropriate. When the SC for a case is <0, this case may have equal similarities 
with cases in another, overlapping cluster and its assignment inside a specific cluster may not 
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be an appropriate fit. In addition, Cohen’s kappa coefficient was used to evaluate the agreement 
between the two analytic approaches. 
Differences in Demographic, Clinical, and Symptom Characteristics and QOL Outcomes 
Descriptive statistics and frequency distributions were calculated for demographic and 
clinical characteristics using SPSS version 23 (IBM, Armonk, NY). For each analytic approach, 
differences in demographic and clinical characteristics and QOL outcomes, among the groups, 
were evaluated using analyses of variance, Kruskal-Wallis, and Chi Square analyses. Post hoc 
contrasts were calculated using the Bonferroni corrected alpha of 0.008 (0.05/6 pairwise 
comparisons). 
RESULTS 
Number of Subgroups Identified Using LCA and K-modes Approaches 
For the LCA, the fit indices for the candidate models are shown in Table 1. The four 
class solution was selected because its BIC was lower than for the 3- and 5-class solutions. In 
addition, the VLMR indicated that a 4-class solution was better than a 3-class solution. 
However, the VLMR for the 5-class solution was not better than the 4-class solution indicating 
that too many classes were extracted. 
Using K-modes, while the average SI for the 3-class solution was slightly larger than the 
average SI for the 4-class solution (Table 2), given this trivial difference and in order to compare 
the differences in demographic, clinical, and symptom characteristics and QOL outcomes 
between the two methods, we used the 4-class solution from the K-modes analysis. 
As shown in Figures 2 and 3, for the LCA and K-modes analyses, respectively, the four 
subgroups were named based on the probability of occurrence of the 25 MSAS symptoms that 
occurred in >30% of the patients. The All High and All Low groups included patients who 
reported relatively high and low occurrence rates for most of the 25 MSAS symptoms, 
respectively. The Moderate Physical and Higher Psychological and Moderate Physical and 
Lower Psychological groups included patients who reported relatively moderate occurrence 
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rates for the majority of the physical symptoms and relatively higher or lower occurrence rates, 
respectively, for the five psychological symptoms (i.e., worrying, feeling irritable, feeling sad, 
feeling nervous, I don’t look like myself).  
The SC diagrams for all of the patient cases within each of the 4 clusters for the LCA 
and K-modes analyses (Figures 1A and 1B) showed that their inefficient assignments were 
mostly within two specific groups (i.e. Moderate Physical and Higher Psychological, Moderate 
Physical and Lower Psychological). Both well (SC >0) and inappropriately (SC <0) clustered 
cases were included within these clusters. As illustrated in the SC diagrams, K-modes assigned 
a larger proportion of cases to these two groups (SC >0). Of note, the two other groups (All 
Low, All High) were well defined and separated using both the LCA and K-modes approaches 
(SC >0.4). 
Pairwise Agreement Between the LCA and K-modes Approaches 
As shown in Table 3, the observed agreement among the four groups was 75.32% and 
the expected agreement was 26.08%. The two analyses separated patients into 4 distinct 
groups with substantial agreement beyond chance (range 0.6-0.7) as measured by the Cohen’s 
coefficient (kappa=0.666).(50) The biggest disagreements between the LCA and K-modes 
approaches were between: a) the Moderate Physical and Lower Psychological (LCA) and All 
Low (K-modes) and b) the Moderate Physical and Higher Psychological (LCA) and All High (K-
modes) groups, with 92 and 101 divergent classifications, respectively.  
Group Characteristics Identified with LCA and K-modes Approaches 
The All Low group consisted of 31.5% (n=419) of the sample using LCA and 40.3% 
(n=536) using K-modes. The probability of occurrence of the MSAS symptoms for this group 
ranged from 0.064 to 0.549 for LCA and 0.093 to 0.647 for K-modes. 
The second largest group identified using LCA was named Moderate Physical and 
Higher Psychological and consisted of 31.3% (n=416) of the sample. Using K-modes, this group 
consisted of 21.1% (n=280) of the patients. The occurrence rates for the majority of the physical 
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symptoms ranged from 0.293 to 0.930 for LCA and from 0.236 to 0.939 for K-modes. For the 
psychological symptoms, the occurrence rates were relatively high. They ranged from 0.541 to 
0.906 for LCA and from 0.582 to 0.811 for K-modes. 
The third largest group identified using LCA (23.8%, n=316) was named the Moderate 
Physical and Lower Psychological group. Using K-modes, this group was the smallest one 
identified (15.4%, n=205). The probability of occurrence for the physical symptoms ranged from 
0.241 to 0.987 for LCA and from 0.210 to 0.956 for K-modes. For the psychological symptoms, 
the range was from 0.142 to 0.282 for LCA and from 0.185 to 0.278 for K-modes.  
The All High group was the smallest one for LCA (13.4%, n=178) and the second largest 
for the K-modes analysis (23.2%, n=308). The probability of occurrence of the MSAS symptoms 
for this group ranged from 0.562 to 0.994 for LCA and from 0.429 to 0.974 for K-modes. 
Differences in Patient Characteristics Among the Groups Identified with LCA and K-
modes Approaches 
Tables 4 and 5 summarize the differences in demographic and clinical characteristics 
among the four groups of patients identified using LCA and K-modes, respectively. For both 
analyses, compared to the “All Low” group, patients in the “Moderate Physical and Higher 
Psychological” and the “All High” groups were significantly younger, had a lower KPS score, had 
a higher SCQ score, were more likely to have breast cancer, and were more likely to report 
depression and back pain. In addition, for both analyses, compared to the “Moderate Physical 
and Lower Psychological” group and the “Moderate Physical and Higher Psychological” group, 
patients in the “All High” group had a lower KPS score and a higher SCQ score. 
Differences in Symptom Occurrence Rates Among the Groups Identified with LCA and K-
modes 
Supplemental Table 1 summarizes differences in symptom occurrence rates among the 
four groups of patients identified using LCA and K-modes. Both analyses identified two groups 
of oncology patients who reported moderate levels of physical symptoms but differentiated on 
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the occurrence of five psychological symptoms (i.e., worrying, feeling irritable, feeling sad, 
feeling nervous, I don’t look like myself). For patients in the Moderate Physical and Higher 
Psychological group, worrying (LCA: 0.906, K-modes: 0.811), feeling sad (LCA: 0.813, K-
modes: 0.811), and feeling irritable (LCA: 0.649, K-modes: 0.657) were among the top 
symptoms. In contrast, in the Moderate Physical and Lower Psychological group, worrying 
(LCA: 0.142, K-modes: 0.278), feeling sad (LCA: 0.161, K-modes: 0.259), and feeling irritable 
(LCA: 0.256, K-modes: 0.224) were among the symptoms with the lowest probability of 
occurrences. The remaining psychological symptoms, namely: “feeling nervous” (Moderate 
Physical and Higher Psychological group: LCA: 0.606, K-modes: 0.693; Moderate Physical and 
Lower Psychological group: LCA: 0.184, K-modes: 0.185) and “I don’t look like myself” 
(Moderate Physical and Higher Psychological group: LCA: 0.541, K-modes: 0.582; Moderate 
Physical and Lower Psychological group: LCA: 0.282, K-modes: 0.259) had significant 
differences between the aforementioned groups for both analyses.  
Across all four groups, lack of energy was the most common symptom. While the 
probability of its occurrence for the total sample was 0.832, values ranged from 0.549 to 0.994 
for LCA and from 0.647 to 0.974 for K-modes. In addition, pain (LCA: 0.944-0.334, K-modes: 
0.834-0.360), difficulty in sleeping (LCA: 0.927-0.458, K-modes: 0.896-0.537), 
numbness/tingling in hands/feet (LCA: 0.798-0.334, K-modes: 0.724-0.356), change in the way 
food tastes (LCA: 0.837-0.274, K-modes: 0.802-0.323), and feeling drowsy (LCA: 0.966-0.243, 
K-modes: 0.860-0.321) occurred in the top ten symptoms across all four groups for both 
analyses. 
Differences in MSAS Summary Scores Among the Groups Identified with LCA and K-
modes 
Table 6 summarizes differences in the MSAS summary scores among the four groups of 
patients identified using LCA and K-modes. For the Physical subscale, the Psychological 
subscale, and the Global Distress index, the differences among the four groups followed the 
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same pattern for both analyses. For the MSAS total score, as well as for the total number of 
MSAS symptoms, the pattern observed using the LCA was in the expected direction (i.e., All 
Low < Moderate Physical and Lower Psychological < Moderate Physical and Higher 
Psychological < All High). For the MSAS total score, as well as for the total number of MSAS 
symptoms, the pattern observed using K-modes was as follows: All Low < Moderate Physical 
and Lower Psychological, Moderate Physical and Higher Psychological and All High (i.e., 0 < 1, 
2, and 3), as well as Moderate Physical and Lower Psychological and Moderate Physical and 
Higher Psychological < All High (i.e., 1 and 2 < 3). 
Differences in QOL Scores Among the Groups Identified with LCA and K-modes 
Table 7 summarizes differences in MQOLS-CA subscale and total scores among the 
four groups of patients identified using LCA and K-modes. For the MQOLS psychological and 
social well-being subscales, and total QOL scores, the differences among the four groups 
followed the same pattern for both analyses (i.e., All Low > Moderate Physical and Lower 
Psychological > Moderate Physical and Higher Psychological > All High). In addition, for the 
physical well-being subscale scores, the differences among the four groups followed the same 
pattern for both analyses (i.e., All Low > Moderate Physical and Lower Psychological, Moderate 
Physical and Higher Psychological, and All High (i.e., 0 > 1, 2, and 3) and Moderate Physical 
and Lower Psychological and Moderate Physical and Higher Psychological > All High (i.e., 1 
and 2 > 3)). 
For the SF12, for both analyses, the MCS scores followed a similar pattern (i.e., All Low 
> Moderate Physical and Lower Psychological > Moderate Physical and Higher Psychological > 
All High). For the PCS scores, the post hoc contrasts were different depending on the method of 
analysis. For LCA, the pattern was All Low > Moderate Physical and Higher Psychological > 
Moderate Physical and Lower Psychological > All High. For the K-modes analysis, the pattern 
was as follows: All Low > Moderate Physical and Lower Psychological, Moderate Physical and 
Higher Psychological and All High (i.e., 0 > 1, 2, and 3), as well as Moderate Physical and 
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Higher Psychological > Moderate Physical and Lower Psychological and All High (i.e., 2 > 1 and 
3). 
DISCUSSION 
This study is the first to evaluate for congruence between the ability of two different 
analytic approaches to identifiy subgroups of oncology patients with distinct symptom profiles. 
Using both LCA and K-modes, four groups of patients with distinct symptom profiles were 
identified. The Cohen’s kappa coefficient of 0.666 represents a moderate level of agreement 
between the two approaches.51-53 Potential reasons for only a moderate level of agreement may 
be related to differences in the underlying assumptions of each of the methods. LCA is a model 
based approach where “clusters” (i.e. classes) are defined by parametric probability distributions 
that can be interpreted to generate homogenous points, while the whole data set is modelled by 
a mixture of such distributions.54 Its key assumption is the conditional independence of the 
observed variables given the latent class. Inside the same class, the presence or the absence of 
one symptom is viewed as unrelated to the presence or absence of all of the others. On the 
other hand, K-modes is a distance-based clustering method that separates clusters as data 
subsets that have small within-cluster distances and large separation from other clusters. K-
modes tries to find clusters that bring similar observations together without making an 
assumption about their distribution or attempt to fit a mixture distribution. Our findings, as well 
as others,54-56 suggest that further research is needed, using both approaches, to determine the 
most sensitive and specific method(s) to risk profile oncology patients based on symptom 
occurrence rates. 
While the absolute percentages of patients in the four groups differed depending on the 
analytic approach, the specific symptom profiles within each of the four groups were very 
similar. In addition, previous work in heterogeneous samples of oncology patients, using a 
different numbers of MSAS symptoms,9,57 found the same four phenotypic profiles identified in 
the current study. Across these three studies, the percentage of patients in the All Low group 
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ranged from 28.0%9 to 40.3% (using K-modes in the current study) and the percentage of 
patients in the All High class ranged from 13.4% (using LCA in the current study) to 27.8%.57 
Across these three studies, these relatively wide ranges may be related to differences in the 
number and types of symptoms evaluated, the timing of the symptom assessments in 
relationship to cancer diagnosis and treatments, and/or the specific cancer diagnoses of the 
patients in each of the studies. That said, these two extreme phenotypes were identified in 
previous studies that used only four symptoms6,7,10,11 or identified only two or three groups.15-17 
Across the two previous studies9,57 and with the two analytic methods used in the current 
study, the consistent phenotypic characteristics associated with membership in the All High 
group were younger age and poorer functional status. The association between younger age 
and a higher symptom burden is consistent with previous studies.6,7 While younger patients may 
receive more aggressive cancer treatments,58 equally plausible hypotheses for this association 
include: that older adults experience a “response shift” in their perception of symptoms;59 that 
chronological age may not be an accurate representation of the biological age of oncology 
patients;60 and/or that accelerated aging occurs with cancer and its treatment.61-63 
Similar to age, the association between a higher symptom burden and poorer functional 
status was reported previously.11,16,18 In the current study and in the one conducted in Norway,57 
that both used the KPS scale, compared to patients in the All Low group who had KPS scores 
between 85 and 95, patients in the All High group reported KPS scores in the mid-70s. This 
difference represents a clinically meaningful change in functional status on this scale. Given that 
patients typically report lower KPS scores than their clinicians,64,65 patients should be 
interviewed not only about the number and severity of their symptoms but about changes in 
functional status during and following cancer treatment. 
An equally important finding in this study and in the two previous studies9,57 is the 
identification of two groups of patients who differentiated based on the occurrence of 
psychological symptoms. While our phenotypic data suggest that these two groups have lower 
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KPS scores and a higher comorbidity profile than the All Low group and better scores for both 
characteristics than the All High group, the demographic and clinical characteristics that 
distinguish between these two “Moderate” groups are not readily apparent. These findings are 
similar to previous reports9,57 and warrant investigation in future studies. An evaluation of 
additional psychosocial characteristics (e.g., coping styles, personality, social support) may 
improve the phenotypic characterization of these two “Moderate” groups. 
In terms of the QOL outcomes, regardless of whether a generic (i.e., SF12) or disease-
specific (i.e., MQOLS-PV) measure was used, the pattern of the differences in scores were in 
the expected direction, namely that as the symptom phenotype worsened, QOL decreased. The 
one interesting finding on Table 7, relates to the PCS scores from the SF12. While none of the 
groups had PCS scores of >50 (i.e., the normative value for the general population in the United 
States), patients in the Moderate Physical and Lower Psychological group had worse scores 
than patients in the Moderate Physical and Higher Psychological group. This finding is 
consistent with the report by Astrup and colleagues.57 Additional research is warranted to 
explain this finding and to determine the specific phenotypic characteristics that distinguish 
between these two Moderate groups. 
In terms of study limitations, patients were recruited at various points in their CTX 
treatment. In addition, the types of CTX were not homogeneous. While we cannot rule out the 
potential contributions of clinical characteristics to patients' symptom experiences, the relatively 
similar percentages of cancer diagnoses, reasons for current treatment, time since cancer 
diagnosis, and evidence of metastatic disease across the four groups, suggest that the patients 
were relatively similar in terms of disease and treatment characteristics. Although it is possible 
that patients in the “All Low” group were receiving more aggressive symptom management 
interventions, the occurrence rates for the five most common symptoms were relatively similar 
across the four classes for both analyses. It is possible that using ratings of frequency, severity 
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or distress to create patients groups would provide additional information on inter-individual 
differences in the symptom experience of these patients.  
 Additional research is warranted using different analytic methods to optimize the 
identification of oncology patients with a higher symptom burden. Future studies can evaluate 
different machine learning approaches, as well as real time collection of different dimensions of 
a patient’s symptom experience (i.e., occurrence, severity, distress) to determine the most 
sensitive and specific methods to use to risk profile patients and design and test more effective 
symptom management interventions. 
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Figure legends 
 
Figure 1A - Silhouette coefficient diagram for the 4-class solution using latent class analysis. 
The sizes of the clusters in the diagram are proportional to their size inside the total sample of 
patients (n=1329). The labels represent the following clslusters: 0 (All Low (n=419, 31.5%)), 1 
(Moderate Physical & Lower Psychological (n=316, 23.8%)), 2 (Moderate Physical & Higher 
Psychological (n=416, 31.3%)) and 3 (All High (n=178, 13.4%). 
 
Figure 1B - Silhouette coefficient diagram for the 4-cluster solution using the K-modes analysis. 
The sizes of the clusters in the diagram are proportional to their size inside the total sample of 
patients (n=1329). The labels represent the following clusters: 0 (All Low (n=536, 40.3%)), 1 
(Moderate Physical & Lower Psychological (n=205, 15.4%)), 2 (Moderate Physical & Higher 
Psychological (n=280, 21.1%)), and 3 (All High (n=308, 23.2%)). 
 
Figure 2 - Symptom occurrence for each of the subgroups identified using latent class analysis 
for the 25 symptoms on the Memorial Symptom Assessment Scale that occurred in >30% of the 
total sample (n=1329) at Time 1 (i.e., prior to next dose of chemotherapy). 
 
Figure 3 - Symptom occurrence for each of the subgroups identified using K-modes analysis for 
the 25 symptoms on the Memorial Symptom Assessment Scale that occurred in >30% of the 
total sample (n=1329) at Time 1 (i.e., prior to next dose of chemotherapy). 
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Table 1 - Latent Class Solutions and Fit Indices for Two- Through Five-Class Solutions 
 
Model                  LL               AIC  BIC             Entropy VLMR 
     
 
3 Class  -10998.00 22150.00 22505.64 .85 413.57* 
 
4 Classa  -10835.22  21876.44 22352.17 .82 325.55* 
 
5 Class -10765.09 21788.17 22383.99 .81 140.27NS 
 
 
aThe four-class solution was selected because the BIC for that solution was lower than the BIC 
for both the 3- and 5-class solutions. In addition, the VLMR for the 4-class solution indicates that 
it fits better than the 3-class solution and the VLMR for the 5-class solution does not fit better 
than the 4-class solution. 
 
*p < .001 
 
Abbreviations: AIC = Akaike’s Information Criterion, BIC = Bayesian Information Criterion, LL = 
log-likelihood, NS = not significant, VLMR = Vuong-Lo-Mendell-Rubin likelihood ratio test for the 
K vs. K-1 model 
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Table 2 – K-modes Solutions and Silhouette Indices for Three- Through Five-Class Solutions 
Model Silhouette Index 
3 Clustera 0.159 
4 Cluster 0.156 
5 Cluster 0.129 
 
aBased on the Silhouette Index, the three-cluster solution performed higher than both the 4- and 
5-cluster solutions.  
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Table 3 - Pairwise Agreement Among the Patient Groups Using Latent Class Analysis and K-modes Analysis 
 
 
aFor LCA – All Low (n=419, 31.5%), Moderate Physical and Lower Psychological (n=316, 23.8%), Moderate Physical and Higher Psychological (n=416, 
31.3%), and All High (n=178, 13.4%). 
 
bFor K-modes analysis – All Low (n=536, 40.3%), Moderate Physical and Lower Psychological (n=205, 15.4%), Moderate Physical and Higher 
Psychological (n=280, 21.1%), and All High (n=308, 23.2%). 
 
cNumber of the patients who were included in both classes 
 
dPercentage of patients from the total sample of 1329 patients 
 
Pairwise agreement among the patient groups All Low
b 
Moderate 
Physical & 
Lower 
Psychological 
Moderate 
Physical & Higher 
Psychological 
All High Total 
n (%) 
nc (%d) nc (%d) nc (%d) nc (%d) 
All Lowa 406 (30.6) 4 (0.3) 9 (0.7) 0 (0.0) 419 (31.5) 
Moderate Physical & Lower Psychological 92 (6.9) 171 (12.9) 23 (1.7) 30 (2.3) 316 (23.8) 
Moderate Physical & Higher Psychological 38 (2.9) 30 (2.3) 247 (18.6) 101 (7.6) 416 (31.3) 
All High 0 (0.0) 0 (0.0) 1 (0.1) 177 (13.3) 178 (13.4) 
Total 536 (40.3) 205 (15.4) 280 (21.1) 308 (23.2) 1,329 (100.0) 
Cohen’s kappa coefficient 
Agreement Expected Agreement Kappa Standard Error Z p-value 
75.32% 26.08% 0.666 0.016 42.64 <0.001 
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Table 4 - Differences in Demographic and Clinical Characteristics Among the Patient Subgroups Using Latent Class Analysis 
 
Characteristic 
All Low 
n=419 (31.5%) 
(0) 
Moderate 
Physical & 
Lower 
Psychological 
n=316 (23.8%) 
(1) 
Moderate 
Physical & 
Higher 
Psychological 
n=416 (31.3%) 
(2) 
All High 
n=178 (13.4%) 
(3) Statistics 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (years) 60.0 (11.2) 57.9 (12.3) 55.3 (12.9) 54.4 (12.0) F(3,1325) = 14.66, p <.001 0 and 1 > 2 and 3 
Education (years) 16.3 (3.1) 16.2 (2.9) 16.4 (3.1) 15.5 (2.9) F(3,1298) = 4.28, p = .005 0 and 2 > 3 
Body mass index (kg/m2)  26.2 (5.5) 26.2 (5.9) 26.0 (5.4) 26.9 (6.4) F(3,1307) = 1.08, p = .358 
Karnofsky Performance Status score  85.8 (11.1) 79.4 (12.2) 78.0 (11.9) 72.3 (11.2) 
F(3,1271) = 62.75,Pp<.001 
0 > 1, 2, and 3 
1 and 2 > 3 
Number of comorbidities  2.1 (1.3) 2.5 (1.4) 2.5 (1.4) 3.0 (1.6) 
F(3,1325) = 19.32, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
SCQ score 4.5 (2.6) 5.6 (3.2) 5.7 (3.1) 7.1 (4.0) 
F(3,1325) = 29.60, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
AUDIT score 3.1 (2.4) 2.5 (1.9) 3.1 (2.7) 3.1 (3.1) F(3,856) = 2.61, p = .05 
Time since cancer diagnosis (years) 1.8 (3.1) 2.1 (4.2) 2.1 (4.4) 1.9 (3.7) KW = 2.64, p = .478 
Time since cancer diagnosis (median) 0.42 0.41 0.44 0.45  
Number of prior cancer treatments  1.5 (1.5) 1.5 (1.5) 1.7 (1.5) 1.8 (1.5) F(3,1312) = 1.25 , p = .290 
Number of metastatic sites including 
lymph node involvement  1.3 (1.2) 1.3 (1.3) 1.3 (1.3) 1.0 (1.1) F(3,1325) = 2.31, p = .075 
Number of metastatic sites excluding 
lymph node involvement  0.8 (1.0) 0.8 (1.1) 0.8 (1.1) 0.6 (0.9) F(3,1325) = 1.85, p = .136 
 % (n) % (n) % (n) % (n)  
Gender 
 Female+ 
 Male 
 Transgender* 
 
67.8 (284) 
32.2 (135) 
0.0 (0) 
 
76.3 (241) 
23.7 (75) 
0.0 (0) 
 
83.7 (348) 
16.1 (67) 
0.2 (1) 
 
89.9 (160) 
10.1 (18) 
0.0 (0) 
X2 = 48.63, p<.001 
0 < 2  
1 < 3 
Ethnicity 
 White 
 Black 
 Asian or Pacific Islander 
 Hispanic Mixed or Other 
 
70.6 (291) 
13.1 (54) 
7.5 (31) 
8.7 (36) 
 
66.6 (207) 
14.8 (46) 
9.3 (29) 
9.3 (29) 
 
75.1 (310) 
8.0 (33) 
5.6 (23) 
11.4 (47) 
 
61.9 (109) 
15.9 (28) 
6.8 (12) 
15.3 (27) 
X2 = 22.96, p = .006 
2 < 3 
NS 
1 and 3 < 2 
NS 
Married or partnered (% yes)  67.7 (279) 64.3 (202) 64.0 (261) 57.4 (101) X2 = 5.78, p = .123 
Lives alone (% yes)  20.9 (86) 20.4 (64) 21.0 (86) 26.6 (47) X2 = 3.03, p = .387 
Child care responsibilities (% yes)  18.5 (76) 21.3 (65) 22.2 (91) 31.0 (54) X
2
 = 11.32, p = .010 
0 < 3 
Care of adult responsibilities (% yes)  5.2 (20) 8.8 (25) 9.6 (36) 8.9 (14) X2 = 5.97, p = .113 
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Abbreviations: AUDIT = Alcohol Use Disorders Identification Test, CTX = chemotherapy, kg = kilograms, KW = Kruskal Wallis; m2 = meter squared, NS = 
not significant, RT = radiation therapy, SCQ = Self-Administered Comorbidity Questionnaire, SD = standard deviation 
 
*Chi Square analysis and post hoc contrasts done without the transgender patient include in the analyses 
+Reference group for the post hoc comparisons 
Currently employed (% yes)  40.0 (165) 34.4 (108) 35.9 (148) 23.3 (41) X
2
 = 15.23, p = .002 
0 and 2 > 3 
Income 
 < $30,000+ 
 $30,000 to <$70,000 
 $70,000 to < $100,000 
 > $100,000 
 
14.4 (52) 
19.7 (71) 
18.9 (68) 
46.9 (169) 
 
18.3 (52) 
21.5 (61) 
16.2 (46) 
44.0 (125) 
 
15.9 (61) 
23.2 (89) 
15.4 (59) 
45.4 (174) 
 
33.1 (54) 
19.0 (31) 
16.0 (26) 
31.9 (52) 
KW, p<.001 
0, 1, and 2 < 3 
Specific comorbidities (% yes) 
 Heart disease 5.5 (23) 7.6 (24) 4.1 (17) 7.3 (13) X2 = 4.91, p = .178 
 High blood pressure 30.5 (128) 33.5 (106) 26.9 (112) 33.1 (59) X2 = 4.48, p = .214 
 Lung disease 9.8 (41) 12.7 (40) 10.6 (44) 14.0 (25) X2 = 3.10, p = .377 
 Diabetes 9.5 (40) 11.4 (36) 6.7 (28) 9.6 (17) X2 = 4.97, p = .174 
 Ulcer or stomach disease 2.9 (12) 4.4 (14) 5.3 (22) 9.0 (16) X
2
 = 10.55, p = .014 
0 < 3 
 Kidney disease 0.7 (3) 1.6 (5) 2.2 (9) 1.1 (2) X2 = 3.27, p = .351 
 Liver disease 7.2 (30) 6.0 (19) 5.8 (24) 7.3 (13) X2 = 0.98, p = .806 
 Anemia or blood disease 7.2 (30) 13.6 (43) 14.4 (60) 17.4 (31) X
2
 = 16.77, p = .001 
0 < 1, 2, and 3 
 Depression 7.2 (30) 11.7 (37) 28.4 (118) 39.3 (70) X
2
 = 119.64, p<.001 
0 and 1 < 2 and 3 
 Osteoarthritis 10.5 (44) 11.4 (36) 13.0 (54) 16.3 (29) X2 = 4.32, p = .229 
 Back pain 15.3 (64) 26.6 (84) 27.6 (115) 44.9 (80) 
X2 = 59.15, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
 Rheumatoid arthritis 2.6 (11) 4.7 (15) 2.6 (11) 3.4 (6) X2 = 3.28, p = .351 
Exercise on a regular basis (% yes)  73.2 (303) 68.8 (212) 74.9 (305) 59.6 (102) X
2
 = 15.41, p = .002 
0 and 2 > 3 
Smoking, current or history of (% yes)  34.2 (142) 37.1 (114) 36.3 (149) 32.6 (57) X2 = 1.40, p = .706 
Cancer diagnosis 
 Breast 
 Gastrointestinal 
 Gynecological 
 Lung 
 
32.9 (138) 
37.2 (156) 
16.7 (70) 
13.1 (55) 
 
39.9 (126) 
33.5 (106) 
13.3 (42) 
13.3 (42) 
 
45.7 (190) 
23.8 (99) 
21.2 (88) 
9.4 (39) 
 
44.9 (80) 
25.8 (46) 
18.5 (33) 
10.7 (19) 
X2 = 34.25, p<.001 
0 < 2 and 3 
0 > 2 and 3; 1 > 2 
1 < 2 
NS 
Type of prior cancer treatment 
 No prior treatment 
 Only surgery, CTX, or RT 
 Surgery & CTX, or Surgery & RT, 
 or CTX & RT 
 Surgery & CTX & RT 
26.5 (108) 
41.0 (167) 
20.6 (84) 
 
11.8 (48) 
29.0 (89) 
41.7 (128) 
17.3 (53) 
 
12.1 (37) 
22.6 (91) 
42.5 (171) 
21.9 (88) 
 
12.9 (52) 
19.9 (35) 
43.8 (77) 
18.2 (32) 
 
18.2 (31) 
KW, p = .063 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 5 - Differences in Demographic and Clinical Characteristics Among the Patient Subgroups Using K-Modes Analysis 
 
Characteristic 
All Low 
n=536 (40.3%) 
(0) 
Moderate 
Physical & Lower 
Psychological 
n=205 (15.4%) 
(1) 
Moderate 
Physical & Higher 
Psychological 
n=280 (21.1%) 
(2) 
All High 
n=308 (23.2%) 
(3) Statistics 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age (years) 59.6 (11.7) 58.1 (12.1) 55.3 (13.1) 54.4 (12.1) 
F(3,1325) = 15.10, p<.001 
0 > 2 and 3 
1 > 3 
Education (years) 16.3 (3.1) 16.0 (2.9) 16.7 (3.0) 15.6 (2.9) F(3,1298) = 6.44, p<.001 0 > 2 and 3 
Body mass index (kg/m2)  26.2 (5.5) 26.3 (5.8) 25.8 (5.2) 26.7 (6.3) F(3,1307) = 1.26, p = .287 
Karnofsky Performance Status score  85.0 (11.3) 77.8 (12.2) 78.6 (11.9) 74.2 (11.7) 
F(3,1271) = 59.38,  p<.001 
0 >1, 2, and 3 
1 and 2 > 3 
Number of comorbidities  2.1 (1.3) 2.6 (1.4) 2.4 (1.4) 2.9 (1.6) 
F(3,1325) = 20.27,  p<.001 
0 <1 and 3 
2 < 3 
SCQ score 4.7 (2.7) 5.9 (3.1) 5.5 (3.0) 6.6 (3.8) 
F(3,1325) = 28.30,  p<.001 
0 <1, 2, and 3  
1 and 2 < 3 
AUDIT score 3.1 (2.2) 2.3 (1.9) 3.1 (2.7) 3.1 (2.9) F(3,856) = 3.92, p = .009 1 < 0, 2 and 3 
Time since cancer diagnosis (years) 2.0 (3.8) 2.2 (4.0) 2.1 (4.3) 1.7 (3.6) KW, p = .831 Time since cancer diagnosis (median) 0.42 0.40 0.45 0.42 
Number of prior cancer treatments  1.6 (1.5) 1.6 (1.5) 1.7 (1.5) 1.6 (1.5) F(3,1312) = 0.41, p = .748 
Number of metastatic sites including 
lymph node involvement  1.3 (1.2) 1.4 (1.3) 1.2 (1.2) 1.1 (1.2) F(3,1325) = 2.33, p = .073 
Number of metastatic sites excluding 
lymph node involvement  0.8 (1.0) 0.9 (1.1) 0.8 (1.1) 0.7 (1.0) F(3,1325) = 1.83, p = .140 
 % (n) % (n) % (n) % (n)  
Gender 
 Female+ 
 Male 
 Transgender* 
 
69.6 (373) 
30.4 (163) 
0.0 (0) 
 
74.1 (152) 
25.9 (53) 
0.0 (0) 
 
83.9 (235) 
15.7 (44) 
0.4 (1) 
 
88.6 (273) 
11.4 (35) 
0.0 (0) 
X2 = 50.10,  p<.001 
0 < 2 and 3 
1 < 3 
 
Ethnicity 
 White 
 Black 
 Asian or Pacific Islander 
 Hispanic Mixed or Other 
 
71.2 (375) 
12.7 (67) 
7.2 (38) 
8.9 (47) 
 
60.7 (122) 
16.9 (34) 
10.9 (22) 
11.4 (23) 
 
77.8 (217) 
8.6 (24) 
4.3 (12) 
9.3 (26) 
 
66.6 (203) 
11.8 (36) 
7.5 (23) 
14.1 (43) 
X2 = 24.93, p = .003 
1 and 3 < 2 
1 > 2 
1 > 2 
NS 
Married or partnered (% yes)  66.9 (354) 64.4 (130) 60.9 (167) 63.0 (192) X2 = 3.16, p = .367 
Lives alone (% yes)  20.7 (109) 20.2 (41) 23.3 (64) 22.5 (69) X2 = 1.12, p = .773 
Child care responsibilities (% yes)  19.4 (102) 17.4 (34) 20.4 (57) 31.0 (93) X
2
 = 19.01, p = .000 
0, 1, and 2 < 3 
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Abbreviations: AUDIT = Alcohol Use Disorders Identification Test, CTX = chemotherapy, kg = kilograms, KW = Kruskal Wallis; m2 = meter squared, NS = 
not significant, RT = radiation therapy, SCQ = Self-Administered Comorbidity Questionnaire, SD = standard deviation 
 
*Chi Square analysis and post hoc contrasts done without the transgender patient include in the analyses 
Care of adult responsibilities (% yes)  6.1 (30) 9.9 (18) 8.3 (21) 9.4 (26) X2 = 4.15, p = .246 
Currently employed (% yes)  38.9 (206) 36.0 (73) 37.5 (104) 25.9 (79) X
2
 = 15.42, p = .001 
0 and 2 > 3 
Income 
 < $30,000+ 
 $30,000 to <$70,000 
 $70,000 to < $100,000 
 > $100,000 
 
15.1 (70) 
19.8 (92) 
18.8 (87) 
46.3 (215) 
 
20.4 (38) 
21.0 (39) 
17.7 (33) 
40.9 (76) 
 
15.1 (39) 
22.8 (59) 
13.1 (34) 
49.0 (127) 
 
25.6 (72) 
22.1 (62) 
16.0 (45) 
36.3 (102) 
KW, p = .001 
0 and 2 < 3 
 
 
 
Specific comorbidities (% yes) 
 Heart disease 6.3 (34) 7.3 (15) 4.6 (13) 4.9 (15) X2 = 2.33, p = .507 
 High blood pressure 30.4 (163) 36.1 (74) 25.7 (72) 31.2 (96) X2 = 6.13, p = .106 
 Lung disease 11.2 (60) 9.3 (19) 12.1 (34) 12.0 (37) X2 = 1.21, p = .752 
 Diabetes 8.8 (47) 15.1 (31) 5.7 (16) 8.8 (27) X
2
 = 12.97, p = .005 
1 > 2 
 Ulcer or stomach disease 3.4 (18) 4.9 (10) 3.9 (11) 8.1 (25) X
2
 = 10.29, p = .016 
0 < 3 
 Kidney disease 0.9 (5) 1.5 (3) 1.4 (4) 2.3 (7) X2 = 2.49, p = .476 
 Liver disease 6.2 (33) 8.3 (17) 5.7 (16) 6.5 (20) X2 = 1.48, p = .688 
 Anemia or blood disease 8.6 (46) 15.1 (31) 9.3 (26) 19.8 (61) X
2
 = 26.75,  p<.001 
0 and 2 < 3 
 Depression 7.5 (40) 13.7 (28) 28.6 (80) 34.7 (107) X
2
 = 115.51,  p<.001 
0 and 1 < 2 and 3 
 Osteoarthritis 9.9 (53) 12.2 (25) 13.2 (37) 15.6 (48) X2 = 6.20, p = .102 
 Back pain 16.0 (86) 29.3 (60) 26.4 (74) 39.9 (123) 
X2 = 60.12,  p<.001 
0 <1, 2, and 3 
2 < 3 
 Rheumatoid arthritis 3.2 (17) 3.9 (8) 1.8 (5) 4.2 (13) X2 = 3.13, p = .372 
Exercise on a regular basis (% yes)  73.6 (388) 69.0 (138) 74.2 (204) 64.4 (192) X
2
 = 9.73, p = .021 
0 > 3 
Smoking, current or history of (% yes)  35.5 (188) 34.0 (68) 37.9 (105) 33.6 (101) X2 = 1.38, p = .710 
Cancer diagnosis 
 Breast 
 Gastrointestinal 
 Gynecological 
 Lung 
 
34.9 (187) 
34.9 (187) 
16.8 (90) 
13.4 (72) 
 
37.1 (76) 
40.5 (83) 
10.7 (22) 
11.7 (24) 
 
47.1 (132) 
20.4 (57) 
22.1 (62) 
10.4 (29) 
 
45.1 (139) 
26.0 (80) 
19.2 (59) 
9.7 (30) 
X2 = 43.25,  p<.001 
0 < 2 and 3 
0 and 1 > 2 and 3 
1 < 2 
NS 
Type of prior cancer treatment 
 No prior treatment 
 Only surgery, CTX, or RT 
 Surgery & CTX, or Surgery & RT, 
 or CTX & RT 
 Surgery & CTX & RT 
 
25.9 (135) 
41.7 (217) 
20.0 (104) 
 
12.5 (65) 
 
30.8 (61) 
37.9 (75) 
19.7 (39) 
 
11.6 (23) 
 
20.1 (55) 
44.3 (121) 
22.7 (62) 
 
12.8 (35) 
 
24.0 (72) 
43.3 (130) 
17.3 (52) 
 
15.3 (46) 
KW, p = .226 
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+Reference group for the post hoc comparisons 
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Table 6 - Differences in Memorial Symptom Assessment Scale Scores Among the Patient Subgroups Using Latent Class Analysis or K-Modes Analysis 
 
 
Abbreviations: MSAS = Memorial Symptom Assessment Scale, SD = standard deviation 
 
aFor LCA – All Low (n=419, 31.5%), Moderate Physical and Lower Psychological (n=316, 23.8%), Moderate Physical and Higher Psychological (n=416, 
31.3%) and All High (n=178, 13.4%). 
 
bFor K-modes analysis – All Low (n=536, 40.3%), Moderate Physical and Lower Psychological (n=205, 15.4%), Moderate Physical and Higher 
Psychological (n=280, 21.13%) and All High (n=303, 23.24%). 
MSAS scores 
All Lowa,b 
(0) 
Moderate 
Physical & 
Lower 
Psychological 
(1) 
Moderate 
Physical & 
Higher 
Psychological 
(2) 
All High 
(3) Statistics 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
PATIENT SUBGROUPS USING LATENT CLASS ANALYSIS 
Physical subscale 0.3 (0.2) 1.0 (0.4) 0.8 (0.4) 1.6 (0.5) F(3,1325) = 578.78, p<.001 0 < 2 < 1 < 3 
Psychological subscale  0.3 (0.3) 0.6 (0.4) 1.3 (0.5) 1.9 (0.6) F(3,1325) = 717.30, p<.001 0 < 1 < 2 < 3 
Global Distress Index 0.4 (0.3) 0.9 (0.4) 1.3 (0.5) 2.1 (0.6) F(3,1305) = 770.22, p<.001 0 < 1 < 2 < 3 
Total Score 0.3 (0.2) 0.7 (0.3) 0.8 (0.3) 1.6 (0.4) F(3,1325) = 11037.63, p<.001 0 < 1 < 2 < 3 
Total number of MSAS symptoms 
(out of 32) 5.6 (2.5) 12.9 (3.2) 14.6 (3.0) 23.0 (3.3) 
F(3,1325) = 1601.27, P = 0.000, 
0 < 1 < 2 < 3 
Total number of MSAS symptoms 
(out of 38) 6.3 (2.9) 14.4 (3.5) 16.1 (3.5) 26.1 (4.4) 
F(3,1325) = 1474.65, p<.001 
0 < 1 < 2 < 3 
PATIENT SUBGROUPS USING K-MODES ANALYSIS 
Physical subscale 0.4 (0.3) 1.1 (0.4) 0.7 (0.4) 1.4 (0.6) F(3,1325) = 578.28, p<.001 0 < 2 < 1 < 3 
Psychological subscale 0.4 (0.3) 0.6 (0.4) 1.3 (0.5) 1.6 (0.7) F(3,1325) = 553.73, p<.001 0 < 1 < 2 < 3 
Global Distress Index 0.4 (0.3) 1.0 (0.4) 1.3 (0.5) 1.8 (0.6) F(3,1305) = 588.21, p<.001 0 < 1 < 2 < 3 
Total Score 0.3 (0.2) 0.8 (0.3) 0.8 (0.3) 1.3 (0.4) 
F(3,1325) = 765.76, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Total number of MSAS symptoms 
(out of 32) 6.7 (3.2) 13.9 (2.8) 13.7 (2.8) 20.6 (4.1) 
F(3,1325) = 1187.40, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Total number of MSAS symptoms 
(out of 38) 7.6 (3.6) 15.2 (3.1) 15.0 (3.3) 23.2 (5.1) 
F(3,1325) = 1068.59, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
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Table 7 - Differences in Quality of Life Scores Among the Patient Subgroups Using Latent Class Analysis or K-Modes Analysis 
 
 
Abbreviations: MCS = Mental Component Summary, MQOLS-PV = Multidimensional Quality of Life Scale – Patient Version, PCS = Physical Component 
Summary, SF12 – Medical Outcomes Study Short Form 12, SD = standard deviation 
 
aFor LCA – All Low (n=419, 31.5%), Moderate Physical and Lower Psychological (n=316, 23.8%), Moderate Physical and Higher Psychological (n=416, 
31.3%) and All High (n=178, 13.4%). 
 
QOL scores 
All Low 
(0) 
 
Moderate 
Physical & 
Lower 
Psychological 
(1) 
Moderate 
Physical & 
Higher 
Psychological 
(2) 
All High 
(3) Statistics 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
PATIENT SUBGROUPS USING LATENT CLASS ANALYSIS 
MQOLS-PV - Physical well-being 7.8 (1.4) 6.5 (1.5) 6.3 (1.5) 4.7 (1.6) 
F(3,1292) = 179.64, p<.001 
0 > 1, 2, and 3 
1 and 2 > 3 
MQOLS-PV - Psychological well-
being 6.5 (1.6) 6.0 (1.6) 4.7 (1.6) 4.0 (1.5) 
F(3,1281) = 154.85, p<.001 
0 > 1 > 2 > 3 
MQOLS-PV - Social well-being 6.9 (1.7) 6.0 (1.8) 5.1 (1.8) 4.1 (1.8) F(3,1274) = 123.13, p<.001 0 > 1 > 2 > 3 
MQOLS-PV – Spiritual well-being 5.5 (2.2) 5.5 (2.1) 5.3 (2.0) 5.6 (2.0) F(3,1286) = 0.61, p = .611 
MQOLS-PV – Total QOL score 6.7 (1.2) 6.0 (1.2) 5.2 (1.2) 4.4 (1.2) F(3,1276) = 177.88, p<.001 0 > 1 > 2 > 3 
SF12 – PCS score 45.6 (9.6) 39.0 (10.1) 41.1 (10.5) 35.7 (9.7) F(3,1225) = 45.76, p<.001 0 > 2 > 1 > 3 
SF12 – MCS score 54.0 (8.4) 51.9 (8.5) 45.4 (9.8) 40.5 (11.1) F(3,1225) = 113.49, p<.001 0 > 1 > 2 > 3 
PATIENT SUBGROUPS USING K-MODES ANALYSIS 
MQOLS-PV - Physical well-being 7.6 (1.5) 6.3 (1.5) 6.5 (1.5) 5.2 (1.7) 
F(3,1292) = 153.99, p<.001 
0 > 1, 2, and 3 
1 and 2 > 3 
MQOLS-PV - Psychological well-
being 6.4 (1.6) 5.9 (1.6) 4.7 (1.6) 4.3 (1.6) 
F(3,1281) = 128.41, p<.001 
0 > 1 > 2 > 3 
MQOLS-PV - Social well-being 6.7 (1.8) 5.9 (1.8) 5.2 (1.8) 4.4 (1.8) F(3,1274) = 115.73, p<.001 0 > 1 > 2 > 3 
MQOLS-PV – Spiritual well-being 5.5 (2.1) 5.5 (2.1) 5.3 (2.0) 5.5 (2.0) F(3,1286) = 0.71, p = .547 
MQOLS-PV – Total QOL score 6.5 (1.2) 5.9 (1.3) 5.3 (1.2) 4.7 (1.3) F(3,1276) = 152.38, p<.001 0 > 1 > 2 > 3 
SF12 – PCS score 44.8 (9.9) 38.1 (9.3) 41.6 (10.3) 37.0 (10.5) 
F(3,1225) = 43.78, p<.001 
0 > 1, 2, and 3 
2 > 1 and 3 
SF12 – MCS score 53.7 (8.3) 51.2 (9.0) 45.3 (10.3) 42.9 (10.5) F(3,1225) = 98.06, p<.001 0 > 1 > 2 > 3 
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bFor K-modes analysis – All Low (n=536, 40.3%), Moderate Physical and Lower Psychological (n=205, 15.4%), Moderate Physical and Higher 
Psychological (n=280, 21.13%) and All High (n=303, 23.24%). 
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Supplemental Table 1 – Differences in Symptom Occurrence Rates Among the Patient Subgroups Using Latent Class Analysis or K-Modes Analysis 
 
Symptom Method 
All Lowa,b 
 
(0) 
Moderate 
Physical & Lower 
Psychological  
(1) 
Moderate 
Physical & Higher 
Psychological 
(2) 
All High 
 
(3) 
Statistics 
Physical Symptoms 
Lack of energy 
LCA 54.9 98.7 93.0 99.4 
X2 = 357.44, p<.001 
0 < 1, 2, and 3 
1 > 2; 2 < 3 
K-Modes 64.7 95.6 93.9 97.4 X
2
 = 221.00, p<.001 
0 < 1, 2, and 3  
Difficult concentrating LCA 18.1 48.4 69.0 97.8 X
2
 =391.45, p<.001 
0 < 1 < 2 < 3 
K-Modes 25.4 36.1 76.1 86.7 X
2
 = 386.45, p<.001 
0 < 1 < 2 < 3 
Feeling drowsy 
LCA 24.3 73.7 70.7 96.6 
X2 = 366.85, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 32.1 71.2 77.9 86.0 
X2 = 309.61, p<.001 
0 < 1, 2, and 3 
1 < 3 
Nausea 
LCA 16.7 63.9 45.4 95.5 
X2 = 358.73, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 22.6 77.6 34.6 82.5 
X2 = 377.42, p<.001 
0 < 1, 2, and 3 
1 > 2; 2 < 3 
Pain 
LCA 33.4 70.3 65.6 94.4 
X2 = 231.14, p<.001 
0 <1, 2, and 3 
1 and 2 < 3 
K-Modes 36.0 75.1 71.1 83.4 
X2 = 233.65, p<.001 
0 < 1, 2, and 3 
2 < 3 
Difficulty sleeping LCA 45.8 71.5 80.5 92.7 X
2
 = 178.97, p<.001 
0 < 1 < 2 < 3 
K-Modes 53.7 69.3 75.7 89.6 
X2 = 125.66, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Dry mouth 
LCA 21.2 65.8 36.8 86.0 
X2 = 282.43, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 26.1 72.2 31.4 73.7 
X2 = 261.36, p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Lack of appetite LCA 14.1 56.0 39.2 84.3 X2 = 292.58, p<.001 
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0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 18.7 71.2 26.8 74.0 
X2 = 349.43, p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Change in the way food 
tastes LCA 27.4 63.3 46.2 83.7 
X2 = 190.76, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 32.3 70.7 32.5 80.2 
X2 = 249.04, p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Numbness/tingling in 
hands/feet LCA 33.4 62.0 51.9 79.8 
X2 = 125.76, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 35.6 75.1 45.0 72.4 
X2 = 158.32, p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Hair loss 
LCA 33.7 61.4 60.8 78.7 
X2 = 128.15, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 34.0 69.8 64.6 72.1 X
2
 = 160.60, p<.001 
0 < 1, 2, and 3 
Constipation 
LCA 21.5 47.5 47.6 78.7 
X2 = 177.03, p<.001 
0 < 1, 2, and 3 
1 < 2 and 3 
K-Modes 22.9 61.5 36.1 74.0 
X2 = 242.11, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
Feeling bloated LCA 10.3 28.8 40.4 77.5 X
2
 = 269.93, p<.001 
0 < 1 < 2 < 3 
K-Modes 16.0 24.4 32.5 69.2 
X2 = 258.27, p<.001 
0 < 2 and 3 
1 and 2 < 3 
Changes in skin 
LCA 11.5 38.9 41.8 77.0 
X2 = 245.68, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 16.4 35.6 36.1 71.4 
X2 = 256.15, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Sweats 
LCA 13.6 27.8 33.7 73.0 
X2 = 208.28, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 17.5 21.0 26.4 66.2 
X2 = 235.56, p<.001 
0 < 2 and 3 
1 and 2 < 3 
Dizziness LCA 6.4 39.9 32.9 70.8 X2 = 260.76, p<.001 
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0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 9.3 56.6 23.6 59.7 
X2 = 304.91, p<.001 
0 < 1, 2, and 3 
1 > 2; 2 < 3 
Hot flashes 
LCA 16.7 33.5 29.3 70.2 
X2 = 166.73, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 21.3 21.5 23.9 64.3 X
2
 = 195.29, p<.001 
0, 1, and 2 < 3 
Problems with sexual 
interest or activity LCA 10.5 24.1 41.8 57.9 
X2 = 175.13, p<.001 
0 < 1 < 2 < 3 
K-Modes 13.2 25.9 30.7 60.7 
X2 = 212.26, p<.001 
0 < 1 and 3 
1 and 2 < 3 
Cough 
LCA 18.4 40.5 30.5 56.7 
X2 = 95.62, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 22.4 31.7 28.2 54.9 X
2
 = 97.52, p<.001 
0, 1, and 2 < 3 
Diarrhea 
LCA 12.9 32.6 32.7 56.2 
X2 = 119.84, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 16.8 38.5 32.9 42.9 X
2
 = 77.50, p<.001 
0 < 1, 2, and 3 
Psychological Symptoms 
Worrying 
LCA 22.4 14.2 90.6 98.9 
X2 = 732.68, p<.001 
0 > 1 
0 and 1 < 2 and 3; 2 < 3 
K-Modes 24.3 27.8 81.1 90.3 
X2 = 488.89, p<.001 
0 and 1 < 2 and 3 
2 < 3 
Feeling irritable LCA 8.4 25.6 64.9 91.6 X
2
 = 500.74, p<.001 
0 < 1 < 2 < 3 
K-Modes 13.8 22.4 65.7 79.5 
X2 = 451.86, p<.001 
0 < 2 < 3 
1 < 2 and 3 
Feeling sad 
LCA 14.3 16.1 81.3 91.6 
X2 = 639.54, p<.001 
0 and 1 < 2 and 3 
2 < 3 
K-Modes 15.7 25.9 81.1 80.5 
X2 = 518.29, p<.001 
0 < 1, 2, and 3 
1 < 2 and 3 
Feeling nervous LCA 9.5 18.4 60.6 87.1 X
2
 = 467.74, p<.001 
0 < 1 < 2 < 3 
K-Modes 10.6 18.5 69.3 70.1 X2 = 454.62, p<.001 
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0 < 1, 2, and 3 
1 < 2 and 3 
I don’t look like myself LCA 13.6 28.2 54.1 74.2 X
2
 = 263.69, p<.001 
0 < 1 < 2 < 3 
K-Modes 14.6 25.9 58.2 67.9 
X2 = 303.48, p<.001 
0 < 1, 2, and 3 
1 < 2 and 3 
Symptoms Not Included Formation of Patient Groups 
Difficulty swallowing 
LCA 4.1 18.7 10.6 35.4 
X2 = 113.35, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 4.7 21.5 8.2 29.5 
X2 = 119.48,  p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Abdominal cramps 
LCA 8.1 21.5 21.9 59.6 
X2 = 190.13, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 10.3 22.4 20.7 45.5 
X2 = 139.63, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Shortness of breath 
LCA 10.3 30.1 28.1 57.3 
X2 = 144.71, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 14.4 30.7 28.2 44.8 
X2 = 94.90, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Difficulty breathing 
LCA 7.4 22.8 17.5 50.0 
X2 = 145.13, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 10.4 21.0 18.9 36.7 
X2 = 84.69, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Chest tightness 
LCA 5.5 16.8 18.0 48.3 
X2 = 156.69, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 6.9 16.6 18.2 37.3 
X2 = 123.91, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Itching 
LCA 12.2 29.1 24.8 47.2 
X2 = 86.76, p<.001 
0 < 1, 2, and 3 
1 < 3 
K-Modes 14.6 27.3 24.3 41.6 
X2 = 77.24, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Weight loss LCA 13.1 30.4 24.3 46.6 X
2
 = 80.44, p<.001 
0 < 1, 2, and 3 
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Abbreviations: LCA = latent class analysis 
 
aFor LCA – All Low (n=419, 31.5%), Moderate Physical and Lower Psychological (n=316, 23.8%), Moderate Physical and Higher Psychological (n=416, 
31.3%) and All High (n=178, 13.4%). 
 
bFor K-modes analysis – All Low (n=536, 40.3%), Moderate Physical and Lower Psychological (n=205, 15.4%), Moderate Physical and Higher 
Psychological (n=280, 21.13%) and All High (n=303, 23.24%). 
 
1 and 2 < 3 
K-Modes 14.2 40.0 17.1 41.9 
X2 = 113.46, p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Increased appetite 
LCA 16.0 23.7 28.8 46.1 
X2 = 61.84, p<.001 
0 < 2 and 3 
1 and 2 < 3 
K-Modes 18.3 22.4 25.4 41.9 X
2
 = 58.54, p<.001 
0, 1 and 2 < 3 
Mouth sores 
LCA 9.1 21.8 24.3 39.3 
X2 = 75.02, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 10.3 23.9 22.5 36.0 
X2 = 80.90, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
Problems with urination 
LCA 5.7 12.3 13.2 38.8 
X2 = 114.92, p<.001 
0 < 1, 2, and 3 
1 and 2 < 3 
K-Modes 6.9 12.2 11.8 29.9 X
2
 = 88.17, p<.001 
0, 1, and 2 < 3 
Weight gain LCA 16.2 25.9 28.8 37.6 X
2
 = 35.37, p<.001 
0 < 1, 2, and 3 
K-Modes 18.1 23.9 28.2 36.4 
X2 = 36.08, p<.001 
0 < 2 and 3 
1 < 3 
Vomiting 
LCA 4.1 16.5 9.6 30.9 
X2 = 91.05, p<.001 
0 < 1, 2, and 3 
1 > 2; 1 and 2 < 3 
K-Modes 5.8 19.0 8.9 22.4 
X2 = 61.61, p<.001 
0 < 1 and 3 
1 > 2; 2 < 3 
Swelling in the arms 
and/or legs LCA 7.6 17.1 14.7 26.4 
X2 = 37.76, p<.001 
0 < 1, 2, and 3 
2 < 3 
K-Modes 8.8 16.1 15.0 23.4 X
2
 = 34.06, p<.001 
0 < 1 and 3 
